- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04486222
Versnelde bilaterale rTMS bij geriatrische depressie
Therapeutisch effect van versnelde bilaterale herhaalde transcraniële magnetische stimulatie op geriatrische depressie: een prospectief dubbelblind, gerandomiseerd gecontroleerd onderzoek
This study aims to evaluate the efficacy of accelerated bilateral repetitive transcranial magnetic stimulation (rTMS) on major depression, anxiety, cognitive function and physiological parameters in elderly depressive patients.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Repeated transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation treatment, showing good therapeutic effect to medicine treatment-refractory patients. Recent studies suggested bilateral DLPFC might be effective to geriatric depression. Accelerated treatment course was reported to have similar therapeutic effect and safety profile with traditional course. The investigators hypothesize accelerated bilateral rTMS is effective to geriatric depression and comorbid anxiety.
Cognitive impairment and decreased parasympathetic tone are common in patients with major depression. The investigators hypothesize cognitive function and physiological indicators improve after accelerated bilateral rTMS.
In this single-center, prospective double-blind, randomized, active-controlled trial, the investigators aim to recruit 100 patients older than 60 years, without neurocognitive disorders, and refractory to one or more antidepressants. The experimental group would receive an rTMS course with high-frequency stimulation at left DLPFC followed by low-frequency inhibition at right DLPFC, two sessions daily, five days a week, and two weeks in total. The standard treatment group would receive an rTMS course with high-frequency stimulation at left DLPFC as standard treatment parameters. Mood, cognition and physiological markers would be monitored every week. The primary outcome is response and remission rate of major depression measured by Hamilton Rating Scale for Depression.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Douliu, Taiwan
- Department of Psychiatry, National Taiwan University Hospital, Yun-Lin Branch
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- age between 60-85 years
- literate and received basic education for at least 2 years
- diagnosis of major depressive disorder, without psychotic features, according to DSM-5
- have a score of 20 or greater on the 17-item Hamilton Depression Rating Scale
- failed to achieve clinical response by at least 1 antidepressant trial of sufficient dosage for at least 4 weeks
- psychoactive agents were in stable doses before randomization
Exclusion Criteria:
- active suicide plans or attempts; or suicide attempts in the last 12 months
- diagnosis of schizophrenia or bipolar disorder according to DSM-5
- have DSM-5-confirmed substance use disorder (excluding tobacco) in the last 3 months
- have delirium, major neurocognitive disorder or MMSE < 24
- current use of bupropion >300 mg/day, tricyclic antidepressant, clozapine, chlorpromazine, foscarnet, ganciclovir, ritonavir, theophylline or anti-epileptic agents excluding benzodiazepines
- history of severe head trauma, epilepsy, multiple sclerosis, stroke, brain tumors, intracranial aneurysm, active intracranial infection, increased intracranial pressure, metallic implants in the brain, major brain surgery or major neurological diseases
- with a cardiac pacemaker or defibrillator
- received rTMS treatment before
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Experimental Group
The experimental group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by low-frequency (1Hz) inhibition at right DLPFC (120% motor threshold, 10 trains, 1200 pulses), two sessions daily with a 1.5-hour inter-session interval (L't active-R't active-1.5 hr-L't active-R't active), five days a week, and two weeks in total. |
Magstim® Super Rapid² Transcranial Magnetic Stimulation System |
|
Actieve vergelijker: Standard Treatment Group
The standard treatment group would receive an rTMS course with high-frequency stimulation (10Hz) at left DLPFC (120% motor threshold, 40 trains, 1600 pulses) followed by sham inhibition at right DLPFC (1Hz, 10 trains, 1200 pulses); after a 1.5-hour inter-session interval, a sham session would be administered at left and right DLPFC (L't active-R't sham-1.5 hr-L't sham-R't sham. The course would be applied five days a week, and two weeks in total. |
Magstim® Super Rapid² Transcranial Magnetic Stimulation System |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Degree of Change in 17-item Hamilton Depression Rating Scale (HAM-D 17)
Tijdsspanne: day 1, day 5, day 12, day 19
|
HAM-D 17 is a scale rating the severity of depression, covering emotional, cognitive and somatic symptoms of depression. Higher scores indicate higher severity. Response to treatment is defined as ≥ 50% decrease in HAM-D 17; remission is defined as ≤ 7 points in HAM-D 17. |
day 1, day 5, day 12, day 19
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Degree of Change in Hamilton Anxiety Rating Scale (HAM-A)
Tijdsspanne: day 1, day 5, day 12, day 19
|
HAM-A is a scale rating the severity of anxiety, covering emotional, cognitive and somatic symptoms of anxiety. Higher scores indicate higher severity. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Mini-Mental State Examination (MMSE)
Tijdsspanne: day 1, day 5, day 12, day 19
|
MMSE is a wildly-used tool to evaluate several cognitive function domains. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Stroop Test
Tijdsspanne: day 1, day 5, day 12, day 19
|
Task 1 (word phase) requests a subject to say a color name string (red, green, blue) printed in black; Task 2 (color phase) requests a subject to say the printed colors (red, green, blue) of letter "x" string; Task 3 (interference phase) requests a subject to say the printed colors of a string of color names (red, green, blue). |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Trail Making Test
Tijdsspanne: day 1, day 5, day 12, day 19
|
Task 1 requests a subject to connect a sequence of 25 consecutive numbers regardless of their colors; Task 2 requires a subject to connect 25 consecutive numbers in alternative colors. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Verbal Fluency Test
Tijdsspanne: day 1, day 5, day 12, day 19
|
This test requests a subject to speak as many names of vegetables, fishes or fruit as possible in 45 seconds. |
day 1, day 5, day 12, day 19
|
|
Degree of Change in Physiological Parameters
Tijdsspanne: day 1, day 5, day 12, day 19
|
ProComp5 Infiniti (SA7525) Biofeedback System would be used. Heart rate variability, skin conductance, body temperature and respiratory rate would be measured. |
day 1, day 5, day 12, day 19
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 201910101RIND
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .